DEXCOM INC 8-K

What Happened DexCom filed an 8‑K reporting that Kevin R. Sayer, who retired as CEO effective January 1, 2026 and was appointed Executive Chairman by the Board, returned from a temporary leave and resumed his duties as Executive Chairman effective March 2, 2026. Mark Foletta resumed his duties as Lead Independent Director. On February 27, 2026 (effective March 2, 2026) Mr. Sayer entered into a letter agreement with the company setting his compensation and equity award terms.

Key Details

• Mr. Sayer’s new annual base salary under the Letter Agreement is $610,000 (effective March 2, 2026).
• The company agreed to grant him restricted stock units (RSUs) with a fair value of $2,350,000, vesting in full on March 8, 2027, subject to continued service.
• Equity awards granted prior to March 2, 2026 will continue to vest per their original terms.
• Mr. Sayer will remain eligible for DexCom’s employee benefit plans for executives but will no longer be eligible for the company’s Amended and Restated Severance & Change in Control Plan as an executive officer.
• The Letter Agreement is filed as Exhibit 10.1 to the Form 8‑K.

Why It Matters This filing clarifies current leadership and compensation arrangements for DexCom’s Executive Chairman, confirming Mr. Sayer’s return and a defined pay/equity package. The RSU grant and salary change are concrete items that affect executive compensation expense and could lead to future share issuance upon vesting. Removing Mr. Sayer from the severance/change‑in‑control plan reduces potential severance exposure tied to his role as an executive officer. Investors should watch future filings (proxy statements and periodic reports) for further details on executive pay, potential dilution from equity awards, and any governance updates.